Body Pharm Retatrutide 32 Pen

Body Pharm Retatrutide 32 Pen: Dosing, Price & 64mg Comparison

The Body Pharm Retatrutide 32 pen is an unregistered, retailer-supplied weekly injectable triple agonist sold in South Africa for roughly half the drug content of the 64mg version, with a published titration starting at 2mg/week and a long-term target of 8mg/week. This article covers the 32mg pen’s four-weekly titration ladder (2 → 4 → 8mg), price-per-mg against the 64mg pen, which lists at R3,200 on BeSkinny, which user profile each pen suits, and retatrutide’s current regulatory status: no SAHPRA, FDA or EMA registration, with the Phase 3 TRIUMPH programme reporting its first read-outs in 2025–2026.

Key Takeaways

• The 32mg pen delivers a structured 12-week titration (2mg → 4mg → 8mg weekly) suited to incretin-naive users, with a price range of R2,100–R3,999 across South African online listings in 2025–2026.
• Price-per-mg favours the 64mg pen (~R50–R55/mg) over the 32mg (~R66–R125/mg) for users already stable at 6–8mg weekly maintenance.
• Retatrutide produced up to 24.2% mean body-weight reduction at 48 weeks in a phase 2 obesity trial, but this remains investigational evidence, not approved-drug data.
• The product carries no SAHPRA, FDA or EMA registration; users should confirm medical suitability with a registered healthcare professional before purchase.
• For sub-2mg dosing or splitting weekly doses, the Retatrutide 10mg vial format allows finer measurement than the pen’s fixed 2mg minimum click.

Read this before you check out.

What Is the Body Pharm Retatrutide 32 Pen?

The Body Pharm Retatrutide 32 pen is a pre-filled, dial-a-dose subcutaneous injection pen containing 32mg of retatrutide as its single active ingredient. It is manufactured under the Body Pharm peptide label and sold through South African online retailers, including BeSkinny. Retatrutide is an investigational triple agonist targeting GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-dependent Insulinotropic Polypeptide) and glucagon receptors, studied in the phase 2 obesity trial published in 2023 and now progressing through the Phase 3 TRIUMPH programme.

What you are physically buying:

• One pre-filled pen with 32mg total drug payload. Exact mL volume and mg/mL concentration are not published on the product listing.
• Dial-a-dose mechanism with fixed markers at 2mg, 4mg and 8mg per click.
• A highest dial marker of 8mg per single click (product-stated, not taken from an approved manufacturer insert).
• Weekly subcutaneous administration, same day each week, with or without food.

Within Body Pharm’s peptide pen line-up, the 32mg retatrutide sits next to the Body Pharm Tirzepatide 30 Pen (dual GLP-1/GIP agonist) and the Somatropin 40 growth hormone pen. For doses below 2mg or slower titration, the Retatrutide 10mg vial allows finer measurement than the pen’s fixed clicks.

Triple Receptor Mechanism: Why Retatrutide Differs

Retatrutide is a single peptide that activates three metabolic receptors — GLP-1, GIP, and glucagon, while semaglutide hits only GLP-1 and tirzepatide hits two (GLP-1 plus GIP). That third lever, the glucagon receptor, separates retatrutide from every other injectable in the current South African weight-loss market.

What each receptor does in practice:

• GLP-1 activation slows gastric emptying and dampens appetite signals from the hypothalamus, the same mechanism behind semaglutide.
• GIP activation improves insulin response after meals and appears to reduce nausea relative to GLP-1-only agents, the tirzepatide effect seen in the Body Pharm Tirzepatide 30 Pen.
• Glucagon activation raises resting energy expenditure and pushes the liver toward fat oxidation, so calories burn faster on top of the appetite suppression.
• Combined action is the proposed reason phase 2 retatrutide produced larger weight loss than dual or single agonists at comparable timeframes.

The headline efficacy figure comes from the phase 2 obesity trial (Jastreboff et al., NEJM 2023): participants on the highest retatrutide dose (12mg weekly) lost a mean 24.2% of body weight at 48 weeks. This was the largest mean weight reduction reported for any incretin-class agent in a phase 2 obesity trial at that time. It should be read as phase 2 evidence, not approved-drug labelling, and the Body Pharm pen is a compounded product rather than the molecule used in the trial.

Retatrutide is engineered for once-weekly subcutaneous dosing, which supports stable dosing intervals between injections. A specific half-life value in hours is not consistently published in open-access pharmacokinetic summaries. For users who need to dose below the pen’s 2mg minimum click, the Retatrutide 10mg vial allows finer measurement than the dial-a-dose pen.

32mg vs 64mg Pen: Side-by-Side Comparison

The 32mg pen suits starters working through the 2mg–8mg titration window, while the 64mg pen is the cheaper-per-mg option for users already stable on 6–8mg weekly who want fewer pen swaps. The table below is based on observed South African online pricing across 2025–2026.

Variant	Total Payload	Max Single Dose (Dial)	Approx. ZAR Retail Range	Price Per mg	Suitable User Profile
Body Pharm Retatrutide 32 Pen	32mg	8mg per click	R2,100–R3,999	~R66–R125/mg	New starters, weeks 1–12 titration, users wanting a lower upfront spend per pen
Body Pharm Retatrutide 64 Pen	64mg	8mg per click	~R3,200–R3,500	~R50–R55/mg	Users already tolerating 6–8mg weekly, want fewer pen changes and lower cost per mg

Price-per-mg methodology

Price-per-mg is calculated as total pen retail price divided by total mg content. The 32mg range is drawn from observed South African listings between roughly R2,100 and R3,999 across 2025–2026. The 64mg baseline of R3,200 comes from the BeSkinny product page. Retail prices on compounded retatrutide shift month to month, so confirm the current listing before purchase.

Which pen makes financial sense

For someone running the full 12-week titration (2mg weeks 1–4, 4mg weeks 5–8, 8mg weeks 9–12), the 32mg pen delivers exactly 24mg of usable drug over those 12 weeks with 8mg residual. Buying the 64mg pen at this stage means stockpiling drug you cannot yet tolerate.

For maintenance users settled at 8mg weekly, the 64mg pen lasts eight weeks per unit at roughly R50/mg, versus roughly R66–R125/mg on the 32mg. Over a year of 8mg weekly dosing (~416mg total), that difference is material. Users dialling below 2mg or splitting doses for tolerance reasons are better served by the Retatrutide 10mg vial, which the pen cannot match for granular measurement.

Neither variant carries SAHPRA registration, so cost comparisons apply to unregistered compounded product, not approved prescription medicine.

Step-by-Step Dosing Titration Protocol for the 32mg Pen

The Body Pharm Retatrutide 32mg pen is set up for a four-weekly step-up from 2mg to a maintenance ceiling of 8mg weekly, reflected in the pen’s 2/4/8mg dial markers. The protocol below is general product guidance, not official prescribing information, and is not medical advice. Consult a registered healthcare professional before initiating.

• Weeks 1–4: 2mg once weekly. Dial to the 2mg marker. Assess gastrointestinal tolerance. Nausea, diarrhoea, vomiting, constipation, and reduced appetite were the most common adverse events in the phase 2 trial for this class of agent.
• Weeks 5–8: 4mg once weekly. Escalate to the 4mg marker only if week-4 GI symptoms are mild or absent. Hold the dose for another 4 weeks if side effects are still settling.
• Weeks 9–12: 8mg once weekly. This is the highest direct dial on the 32mg pen. Product guidance describes 8mg weekly as a long-term maintenance target for weight loss, with lower maintenance permitted under practitioner supervision.
• Week 13 onward: maintenance at 4–8mg weekly. Sit at the lowest dose that delivers continued response. Doses higher than 8mg per injection should be treated as practitioner-only.

This four-weekly step-up mirrors the escalation approach used in the phase 2 trial, where a lower 2mg starting dose helped mitigate early GI side effects. That was an investigational trial protocol, not an approved label, and no SAHPRA, FDA or EMA authorisation exists for retatrutide as of 2026.

Injection technique and storage

Inject subcutaneously into the abdomen, outer thigh, or upper arm, rotating sites each week to reduce injection-site reactions. Same day each week, with or without food. Store the pen refrigerated at 2–8°C, keep it in its original carton away from light, and do not freeze. Discard any pen that has frozen, even if it later thaws clear.

Users who need to dose below 2mg or split weekly doses for tolerance should consider the Retatrutide 10mg vial, since the pen’s lowest dial is 2mg. Those weighing a dual-agonist alternative can compare the Body Pharm Tirzepatide 30 Pen on mechanism and side-effect profile.

Retatrutide for Weight Loss: What the Clinical Data Shows

Retatrutide produced up to 24.2% mean body-weight reduction at 48 weeks in the highest-dose (12mg weekly) cohort of the phase 2 obesity trial published by Jastreboff and colleagues in the New England Journal of Medicine in 2023. This is the figure most commonly quoted for retatrutide, and it comes directly from that dataset.

The phase 2 trial randomised 338 adults with obesity across placebo and four retatrutide dose arms (1, 4, 8, 12mg weekly), with mean weight loss scaling by dose: roughly 17% at 4mg, 23% at 8mg, and 24% at 12mg by week 48. Secondary outcomes moved in the expected direction, with reported improvements in fasting glucose, insulin sensitivity markers, triglycerides, and blood pressure, consistent with a GLP-1/GIP/glucagon triple agonist acting on hepatic and adipose tissue alongside appetite pathways.

What this evidence does not prove

These are phase 2 results in a screened, supervised trial population. The larger Phase 3 TRIUMPH programme, enrolling over 5,800 participants across obesity and diabetes indications, began reporting its first read-outs in 2025–2026, but retatrutide is not yet an approved or registered medicine. Treat the 24.2% figure as a trial ceiling, not a personal forecast.

Retatrutide is also being studied for type 2 diabetes, with the same triple-agonist mechanism targeting glycaemic control alongside weight. Buyers of the Body Pharm Retatrutide 32 Pen should note that real-world response varies with diet, baseline weight, adherence, and tolerance of GI side effects, and that the Body Pharm pen is an unregistered compounded product, not the branded molecule used in the trial. Those weighing a dual-agonist with more mature outcome data may prefer the Body Pharm Tirzepatide 30 Pen instead.

Retatrutide for Type 2 Diabetes: Secondary Benefits

Retatrutide shows glucose-lowering effects alongside weight loss in phase 2 data, but it is not approved for type 2 diabetes treatment anywhere as of 2026. The molecule’s glucagon receptor agonism increases hepatic glucose handling and energy expenditure, while the GLP-1 and GIP components drive insulin secretion and satiety in the same way as tirzepatide.

In the phase 2 obesity trial, participants on retatrutide showed improvements in fasting glucose, insulin sensitivity markers, triglycerides, and blood pressure across the 4mg, 8mg, and 12mg arms at 48 weeks. A separate phase 2 trial in adults with type 2 diabetes reported dose-dependent HbA1c reductions alongside weight loss, though full Phase 3 outcome data in diabetes only began appearing from 2025–2026 onward.

What this means for South African T2D patients

If you have type 2 diabetes and are considering the Body Pharm Retatrutide 32 Pen, speak to an endocrinologist before injecting. The pen is an unregistered compounded product, not a SAHPRA-approved diabetes medicine, and stacking it on metformin, sulfonylureas, or insulin without supervision risks hypoglycaemia. Patients who want a dual-agonist with more mature diabetes outcome data may prefer the Body Pharm Tirzepatide 30 Pen, and those needing sub-2mg starting doses sometimes choose the Retatrutide 10mg vial for finer titration.

Regulatory & Safety Status in South Africa

Retatrutide is not approved for sale as a finished medicine by SAHPRA, the FDA, or the EMA as of 2026. The Phase 3 TRIUMPH programme (over 5,800 participants) is registrational, with the earliest projected regulator approvals expected in the late-2026–2027 window. No Body Pharm Retatrutide pen listing displays a SAHPRA registration number, which places these pens in unregistered or compounded territory.

Disclaimer: The Body Pharm Retatrutide 32 Pen is an unregistered product. It is not a SAHPRA-approved medicine. Information on this page is for education and product comparison only and is not medical advice. Consult a registered South African medical practitioner or pharmacist before purchasing or injecting any peptide.

Under the Medicines and Related Substances Act (Act 101 of 1965, as amended), unregistered medicines may not be advertised or sold for therapeutic use in South Africa without authorisation. SAHPRA and the South African Pharmacy Council have taken enforcement action against the unlawful manufacture and distribution of unregistered GLP-1 and GIP weight-loss injectables. Whether a specific compounded peptide pen falls inside or outside that framework is a question for a pharmacist or healthcare lawyer, not a retailer.

What this means before you click “buy”

1. Confirm with a registered doctor or pharmacist that retatrutide is appropriate for your medical history, because the product is unregistered and carries unknown purity risk.
2. Ask the retailer in writing whether the product is registered with SAHPRA and request a batch certificate of analysis to verify drug content.
3. Treat marketing copy on retailer pages as retailer-sourced, not regulator-verified, since no official labelling exists.
4. For a more clinically mature dual-agonist with broader trial data, consider the Body Pharm Tirzepatide 30 Pen; for sub-2mg titration steps the pen cannot reach, the Retatrutide 10mg vial is the alternative format.

Who Should Consider the 32mg Pen vs Other Options?

The Body Pharm Retatrutide 32mg pen is best suited to adults new to incretin therapy who need a structured 2mg–8mg weekly titration over roughly 12 weeks before deciding whether to escalate. If you have already tolerated 6mg or 8mg weekly for several months, the 32mg pen will run out in four weeks at maintenance dose, and the 64mg pen becomes the cheaper-per-mg refill option.

The 32mg pen fits you if

1. Your BMI is ≥30, or 27–29.9 with a weight-related comorbidity such as hypertension or type 2 diabetes, matching the entry criteria used in the phase 2 retatrutide trial.
2. You are incretin-naive, or stepping across from semaglutide/liraglutide and want a slow 4-weekly dose climb to assess tolerance.
3. You want to cap your initial financial exposure at one smaller pen rather than committing to 64mg of product before knowing how you tolerate the GI side-effect profile, since nausea, diarrhoea, and vomiting were the dominant phase 2 adverse events.

When a different product makes more sense

• Already at 6–8mg weekly and tolerating it well: the Body Pharm Retatrutide 64 Pen at roughly R3,200 gives you about two months of 8mg dosing per pen and a lower price-per-mg.
• Struggled with glucagon-related effects (heart rate rises, intense GI): the dual-agonist Body Pharm Tirzepatide 30 Pen removes the glucagon receptor activity that retatrutide adds.
• Need micro-doses below 2mg, or want to split 1.5mg/2.5mg increments: the pen cannot dial under 2mg, so the Retatrutide 10mg vial with an insulin syringe is the only format that allows it.

Anyone with a personal or family history of medullary thyroid carcinoma, MEN2 (Multiple Endocrine Neoplasia type 2), or known hypersensitivity to GLP-1/GIP/glucagon analogues should not use any retatrutide product, and every candidate should clear the decision with a registered South African practitioner before purchasing.

Where to Buy & Current Price Range in South Africa

Expect to pay between R2,100 and R3,999 for a Body Pharm Retatrutide 32mg pen across South African online retailers in 2025–2026, with most listings clustering around R3,300–R3,600. The pen is stocked at BeSkinny. Prices shift week-to-week with ZAR exchange rates and stock cycles, so confirm the live price before checkout rather than relying on this range.

What to check before paying

A reputable South African supplier should show the following at minimum:

1. Clear product labelling stating “32mg” total content and the 2/4/8mg dial markers.
2. Cold-chain or insulated shipping, because retatrutide is a peptide and degrades at sustained room temperature.
3. A stated return, refund or damaged-pen replacement policy to protect your purchase.
4. The option of a practitioner consultation, since the product is not SAHPRA-registered and titration above 8mg requires clinical oversight.

Purity and batch authenticity cannot be independently verified from a product listing alone, so ask the retailer for a Certificate of Analysis before buying. For sub-2mg dosing, the Retatrutide 10mg vial sits in the same catalogue.

Frequently Asked Questions

How many injections does the 32mg pen provide?

Dose math: 32mg divided by 2mg starting dose = 16 weekly injections at the week 1–4 level; 32mg divided by 4mg = 8 injections at the week 5–8 level; 32mg divided by 8mg = 4 injections at the week 9+ maintenance dose. Following the standard 4-week step-up, a single pen typically lasts a user through roughly 6–8 weekly shots before a refill is needed.

Can I use the 32mg pen if I have type 2 diabetes?

Retatrutide has been studied in adults with type 2 diabetes in a phase 2 trial but has no SAHPRA, FDA or EMA approval for diabetes as of 2026. Combining it with insulin, sulfonylureas or other glucose-lowering drugs without supervision risks hypoglycaemia, because the triple agonist will lower blood sugar on top of existing therapy. Consult a healthcare professional before using any incretin agonist alongside existing diabetes therapy.

What is the difference between retatrutide and tirzepatide?

Tirzepatide is a dual GLP-1/GIP agonist (Mounjaro, Zepbound) already approved internationally; retatrutide is a triple agonist adding glucagon receptor activity, which phase 2 data linked to up to ~24% mean weight loss at 48 weeks versus tirzepatide’s ~21% at 72 weeks in the SURMOUNT-1 phase 3 trial. For the dual-agonist option, see the Body Pharm Tirzepatide 30 Pen.

Does the pen need to be refrigerated?

Yes. Retatrutide is a peptide and should be stored at 2–8°C, kept out of direct light, and not frozen, because peptide bonds break down at higher temperatures and freeze-thaw cycles denature the molecule. If the pen arrives warm, request a replacement before injecting.

Is a prescription required to buy retatrutide in South Africa?

Retatrutide is not SAHPRA-registered, so it sits outside the standard prescription framework. Some online suppliers sell pens without a script, but the Medicines and Related Substances Act restricts unregistered medicines for therapeutic use, and SAHPRA has acted against unregistered GLP-1 weight-loss products. Consult a healthcare professional and obtain informed clinical oversight before purchasing.

What side effects should I watch for?

Nausea, vomiting, diarrhoea, constipation and decreased appetite were the most common adverse events in the phase 2 trial, alongside injection-site reactions and transient heart-rate increases. Severe or persistent symptoms warrant stopping the drug and contacting a clinician. For sub-2mg micro-dosing to reduce GI load, the Retatrutide 10mg vial gives finer control than the pen.

Next Steps

Before purchasing the Body Pharm Retatrutide 32 Pen, take these three actions:

1. Consult a registered South African healthcare professional to confirm retatrutide is medically appropriate for your weight, BMI, comorbidities, and current medications.
2. Request a Certificate of Analysis from the retailer to verify drug content and purity, since the product is unregistered and batch quality cannot be independently verified.
3. Compare your options: if you are already tolerating 6–8mg weekly, the 64mg pen offers better value; if you need sub-2mg dosing, the Retatrutide 10mg vial is the only format that allows it.

References

1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (Jastreboff AM, et al.). New England Journal of Medicine, 2023.
2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial (Rosenstock J, et al.). The Lancet, 2023.
3. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism, 2026.
4. SAHPRA and the SAPC Crack Down on Unlawful Manufacturing of Unregistered GLP-1/GIP Medicines. South African Health Products Regulatory Authority, 2026.
5. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1; Jastreboff AM, et al.). New England Journal of Medicine, 2022.